SCHEMBL652871

SCHEMBL652871

Nc1ccccc1C(=O)Nc1[nH]nc2cc(C(=O)O)oc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 1/20 0.43
ALPI P09923 1/20 0.43
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 4/20 0.41
GAA P10253 2/20 0.41
HSD17B10 Q99714 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
FADS1 O60427 3/20 0.41
HDAC1 Q13547 2/20 0.40
P2RX1 P51575 1/20 0.39
PYGL P06737 1/20 0.38
POLB P06746 2/20 0.38
MAPT P10636 2/20 0.38
TDP1 Q9NUW8 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651482 0.83 MEN1 (0.51) NPC1RAB9AALDH1A1GAASMN1; SMN2
SCHEMBL651126 0.80 NPC1 (0.41) ALPLALPINPC1RAB9AALDH1A1
SCHEMBL653180 0.79 NPC1 (0.41) ALPLALPINPC1RAB9AALDH1A1
SCHEMBL653512 0.78 INSR (0.49) NPC1RAB9A
SCHEMBL4088694 0.74 HCAR2 (0.33) POLBMAPTKMT2AGPR35
SCHEMBL7717671 0.66 NPC1 (0.72) NPC1RAB9AALDH1A1KDM4EHSD17B10
SCHEMBL7722705 0.66 NPC1 (0.72) NPC1RAB9AALDH1A1KDM4EHSD17B10
SCHEMBL4088612 0.66 NPC1 (0.48) NPC1RAB9AALDH1A1KDM4EGAA
SCHEMBL1140055 0.65 PTGS1 (0.68) NPC1RAB9AALDH1A1KDM4EHSD17B10
SCHEMBL4511180 0.65 NPC1 (0.66) NPC1RAB9AALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119641-B2 1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-21 US disclosed
EP-2051981-B1 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2010-08-25 EP disclosed
US-20090239924-A1 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-09-24 US disclosed
EP-2051981-A1 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2009-04-29 EP disclosed
WO-2007138017-A1 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239924-A1 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS IGF1R, CDK1, CDK15 ALPL 3522/4885ALPI 2761/4885NPC1 1674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.